SCHEMBL27218946

SCHEMBL27218946

Oc1cc(C(F)F)nc(SCc2ncc(-c3ccccc3Cl)o2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.35
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.34
ATM Q13315 2/20 0.33
MEN1 O00255 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
POLB P06746 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRE P78334 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218736 0.84 ALDH1A1 (0.35) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218774 0.83 FFAR1 (0.40) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218687 0.82 ALDH1A1 (0.37) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218878 0.82 SMN1; SMN2 (0.43) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218884 0.81 HPGD (0.35) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218880 0.79 SMN1; SMN2 (0.42) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218643 0.79 MEN1 (0.36) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218747 0.77 ALDH1A1 (0.39) HPGDALDH1A1SMN1; SMN2USP2ATM
SCHEMBL31494295 0.77 HSP90AA1 (0.42) HPGDALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL27218760 0.77 MAPK1 (0.48) HPGDALDH1A1SMN1; SMN2USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 HPGD 3042/4885ALDH1A1 1767/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.